Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01339260 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
A Phase 3 study, sponsored by Helsinn Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,455
- Enrollment target
NCT01339260: Completed Phase 3 study, sponsored by Helsinn Healthcare.
NCT01339260 is a Phase 3 study that has completed, run by Helsinn Healthcare. The registered enrollment target is 1,455 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01339260, a Phase 3 study, has completed, sponsored by Helsinn Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,455 participants
- Enrollment target
Study Summary
NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy.
Interventions
- DRUG Dexamethasone
- DRUG Palonosetron
- DRUG Netupitant and Palonosetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,455 participants |
| Start Date | 2011-04 |
| Phase | Phase 3 |
What the finished NCT01339260 record still lists
NCT01339260 is an interventional study that assigns participants to a tested intervention. Its 1,455 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% higher).
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01339260 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01339260 about?
NCT01339260 is a clinical study titled "An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting". NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effect...
What is the current status of trial NCT01339260?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,455 participants. The study started on 2011-04.
What interventions are being tested in trial NCT01339260?
The interventions under investigation include: Dexamethasone (DRUG), Palonosetron (DRUG), Netupitant and Palonosetron (DRUG).
Who is sponsoring clinical trial NCT01339260?
This trial is sponsored by Helsinn Healthcare, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01339260's enrollment target sits among peer trials
1,455 166th of 2000 higher than 1,835 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia